Search

Your search keyword '"Gubonina, Irina"' showing total 12 results
Start Over Author "Gubonina, Irina"
12 results on '"Gubonina, Irina"'

1. Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease

Author

Ungaro, Ryan C., Yzet, Clara, Bossuyt, Peter, Baert, Filip J., Vanasek, Thomas, D’Haens, Geert R., Joustra, Vincent Wilhelmus, Panaccione, Remo, Novacek, Gottfried, Reinisch, Walter, Armuzzi, Alessandro, Golovchenko, Oleksandr, Prymak, Olga, Goldis, Adrian, Travis, Simon P., Hébuterne, Xavier, Ferrante, Marc, Rogler, Gerhard, Fumery, Mathurin, Danese, Silvio, Rydzewska, Grazyna, Pariente, Benjamin, Hertervig, Erik, Stanciu, Carol, Serrero, Melanie, Diculescu, Mircea, Peyrin-Biroulet, Laurent, Laharie, David, Wright, John P., Gomollón, Fernando, Gubonina, Irina, Schreiber, Stefan, Motoya, Satoshi, Hellström, Per M., Halfvarson, Jonas, Butler, James W., Petersson, Joel, Petralia, Francesca, and Colombel, Jean-Frederic

Published
2020
Full Text
View/download PDF

2. Clinical guidelines. Crohn’s disease (К50), adults

Author

Shelygin, Yury A., primary, Ivashkin, Vladimir T., additional, Achkasov, Sergey I., additional, Reshetov, Igor V., additional, Maev, Igor V., additional, Belousova, Elena A., additional, Vardanyan, Armen V., additional, Nanaeva, Bella A., additional, Adamyan, Leila V., additional, Drapkina, Oksana M., additional, Namazova-Baranova, Leila S., additional, Razumovsky, Aleksandr Yu., additional, Revishvili, Amiran Sh., additional, Khatkov, Igor E., additional, Shabunin, Aleksey V., additional, Livzan, Maria A., additional, Sazhin, Aleksandr V., additional, Timerbulatov, Vil M., additional, Khlynova, Olga V., additional, Abdulganieva, Diana I., additional, Abdulkhakov, Rustem A., additional, Aleksandrov, Timofey L., additional, Alekseeva, Olga P., additional, Alekseenko, Sergey A., additional, Anosov, Ivan S., additional, Bakulin, Igor G., additional, Barysheva, Olga Yu., additional, Bolikhov, Kirill V., additional, Veselov, Viktor V., additional, Golovenko, Oleg V., additional, Gubonina, Irina V., additional, Dolgushina, Anastasia I., additional, Zhigalova, Tatiana N., additional, Kagramanova, Anna V., additional, Kashnikov, Vladimir N., additional, Knyazev, Oleg V., additional, Kostenko, Nikolay V., additional, Likutov, Aleksey A., additional, Lomakina, Ekaterina Y., additional, Loranskaya, Irina D., additional, Mingazov, Airat F., additional, Moskalev, Aleksey I., additional, Nazarov, Ilya V., additional, Nikitina, Natalia V., additional, Odintsova, Alfia H., additional, Omelyanovsky, Vitaly V., additional, Osipenko, Marina F., additional, Оshchepkov, Аndrey V., additional, Pavlenko, Vladimir V., additional, Poluektova, Elena A., additional, Rodoman, Grigory V., additional, Segal, Anastasia M., additional, Sitkin, Stanislav I., additional, Skalinskaya, Maria I., additional, Surkov, Andrey N., additional, Sushkov, Oleg I., additional, Tarasova, Larisa V., additional, Uspenskaya, Yulia B., additional, Frolov, Sergey A., additional, Chashkova, Elena Yu., additional, Shifrin, Oleg S., additional, Shcherbakova, Olga V., additional, Shchukina, Oksana B., additional, Shkurko, Tatiana V., additional, and Makarchuk, P. A., additional

Published
2023
Full Text
View/download PDF

4. Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians

Author

Simanenkov, Vladimir I., primary, Maev, Igor V., additional, Tkacheva, Olga N., additional, Alekseenko, Sergei A., additional, Andreev, Dmitry, additional, Bakulina, Natalia V., additional, Bakulin, Igor G., additional, Bordin, Dmitry S., additional, Vlasov, Timur D., additional, Vorobyeva, Natalya M., additional, Grinevich, Vladimir B., additional, Gubonina, Irina V., additional, Drobizhev, Michail Y., additional, Efremov, Nikolay S., additional, Karateev, Andrey E., additional, Kotovskaya, Yulia V., additional, Kravchuk, Iurii, additional, Krivoborodov, Grigory G., additional, Kulchavenya, Ekaterina V., additional, Lila, Aleksander M., additional, Maevskaya, Marina V., additional, Nekrasova, Anna S., additional, Poluektova, Elena A., additional, Popkova, Tatiana V., additional, Sablin, Oleg A., additional, Solovyeva, Olga I., additional, Suvorov, Alexander N., additional, Tarasova, Galina N., additional, Trukhan, Dmity I., additional, and Fedotova, Anastasia V., additional

Published
2022
Full Text
View/download PDF

6. A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients With Ulcerative Colitis, Using the Pictorial Representation of Illness and Self-measure Tool

Author

Ghosh, Subrata, primary, Sensky, Tom, additional, Casellas, Francesc, additional, Rioux, Louis-Charles, additional, Ahmad, Tariq, additional, Márquez, Juan R, additional, Vanasek, Tomas, additional, Gubonina, Irina, additional, Sezgin, Orhan, additional, Ardizzone, Sandro, additional, Kligys, Kristina, additional, Petersson, Joel, additional, Suzuki, Yasuo, additional, and Peyrin-Biroulet, Laurent, additional

Published
2020
Full Text
View/download PDF

7. Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY

Author

Ungaro, Ryan C., primary, Jordan, Robyn, additional, Yzet, Clara, additional, Bossuyt, Peter, additional, Baert, Filip J., additional, Vanasek, Tomas, additional, D'Haens, Geert R., additional, Joustra, Vincent W., additional, Panaccione, Remo, additional, Novacek, Gottfried, additional, Reinisch, Walter, additional, Armuzzi, Alessandro, additional, Golovchenko, Oleksandr, additional, Olga, Prymak, additional, Goldis, Adrian, additional, Travis, Simon P., additional, Hebuterne, Xavier, additional, Ferrante, Marc, additional, Rogler, Gerhard, additional, Fumery, Mathurin, additional, Danese, Silvio, additional, Rydzewska-Wyszkowska, Grazyna, additional, Pariente, Benjamin, additional, Hertervig, Erik, additional, Stanciu, Carol, additional, Serrero, Mélanie, additional, Diculescu, Mircea, additional, Peyrin-Biroulet, Laurent, additional, Laharie, David, additional, Wright, John P, additional, Gomollon, Fernando, additional, Gubonina, Irina, additional, Schreiber, Stefan, additional, Motoya, Satoshi, additional, Hellström, Per M., additional, Halfvarson, Jonas, additional, and Colombel, Jean Frederic, additional

Published
2020
Full Text
View/download PDF

8. Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM

Author

Ungaro, Ryan C., Yzet, Clara, peter bossuyt, Baert, Filip J., Vanasek, Tomas, D Haens, Geert R., Joustra, Vincent W., Panaccione, Remo, Novacek, Gottfried, Armuzzi, Alessandro, Golovchenko, Oleksandr, Olga, Prymak, Goldis, Adrian, Travis, Simon P., Hebuterne, Xavier, Ferrante, Marc, Rogler, Gerhard, Fumery, Mathurin, Danese, Silvio, Rydzewska, Grazyna, Pariente, Benjamin, Hertervig, Erik, Stanciu, Carol, Grimaud, Jean-Charles, Diculescu, Mircea, Peyrin-Biroulet, Laurent, Laharie, David, Wright, John P., Gomollon, Fernando, Gubonina, Irina, Schreiber, Stefan, Motoya, Satoshi, Hellstrom, Per M., Halfvarson, Jonas, and Colombel, Jean Frederic

Abstract

Background We aimed to describe the long-term impact of achieving endoscopic and deep remission among participants in the effect of tight control management on CD (CALM) trial. Methods We analysed medical records from patients with follow-up data since end of CALM. Patients were stratified by outcomes in CALM at 1 year: clinical remission (Crohn’s disease activity index, CDAI Results One hundred twenty-two patients with median age 29 years (IQR 22.5–37) and median disease duration 0.2 years (IQR 0.1–0.8) were included. Median follow-up time from end of CALM was 3.02 years (range 0.05–6.26 years). Fifty per cent were randomised to the tight control arm. There were no significant differences in baseline characteristics in patients with follow-up data and those lost to follow-up with the exception of a slightly higher CDEIS score in patients lost to follow-up (14.6 vs. 12.9, p = 0.04). Thirty-four patients (27.9%) had a major adverse outcome during follow-up. Patients in clinical remission at 1 year did not have significantly lower rates of the composite endpoint (log-rank p = 0.15). Patients in endoscopic and deep remission at the end of CALM were significantly less likely to have a major adverse event over time (Figures 1 and 2). After adjusting for age, disease duration, prior surgery, prior stricture, and randomisation arm, endoscopic remission (aHR 0.44, 95% CI 0.20–0.96, p = 0.038) and deep remission (aHR 0.25, 95% CI 0.09–0.72, p = 0.01) were significantly associated with lower risk of major adverse events. Conclusions Early CD patients who achieve endoscopic or deep remission after 1 year of intensive treatment are less likely to have disease progression over a median of 3 years.

Published
2019
Full Text
View/download PDF

9. Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm

Author

Ungaro, Ryan C., primary, Yzet, Clara, additional, Bossuyt, Peter, additional, Baert, Filip J., additional, Vanasek, Tomas, additional, D'Haens, Geert R., additional, Joustra, Vincent W., additional, Panaccione, Remo, additional, Novacek, Gottfried, additional, Armuzzi, Alessandro, additional, Golovchenko, Oleksandr, additional, Olga, Prymak, additional, Goldis, Adrian, additional, Travis, Simon P., additional, Hebuterne, Xavier, additional, Ferrante, Marc, additional, Rogler, Gerhard, additional, Fumery, Mathurin, additional, Danese, Silvio, additional, Rydzewska, Grazyna, additional, Pariente, Benjamin, additional, Hertervig, Erik, additional, Stanciu, Carol, additional, Grimaud, Jean-charles, additional, Diculescu, Mircea, additional, Peyrin-Biroulet, Laurent, additional, Laharie, David, additional, Wright, John P, additional, Gomollon, Fernando, additional, Gubonina, Irina, additional, Schreiber, Stefan, additional, Motoya, Satoshi, additional, Hellström, Per M., additional, Halfvarson, Jonas, additional, and Colombel, Jean Frederic, additional

Published
2019
Full Text
View/download PDF

10. A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients With Ulcerative Colitis, Using the Pictorial Representation of Illness and Self-measure Tool.

Author

Ghosh, Subrata, Sensky, Tom, Casellas, Francesc, Rioux, Louis-Charles, Ahmad, Tariq, Márquez, Juan R, Vanasek, Tomas, Gubonina, Irina, Sezgin, Orhan, Ardizzone, Sandro, Kligys, Kristina, Petersson, Joel, Suzuki, Yasuo, and Peyrin-Biroulet, Laurent

Abstract

Background The understanding the Impact of ulcerative COlitis aNd Its assoCiated disease burden on patients study [ICONIC] was a 2-year, global, prospective, observational study evaluating the cumulative burden of ulcerative colitis [UC] using the Pictorial Representation of Illness and Self-Measure [PRISM] tool that is validated to measure suffering, but has not previously been used in UC. Methods ICONIC enrolled unselected outpatient clinic attenders with recent-onset UC. Patient- and physician-reported outcomes including PRISM, the Short Inflammatory Bowel Disease Questionnaire [SIBDQ], the Patient Health Questionnaire [PHQ-9], and the Simple Clinical Colitis Activity Indexes [patient: P-SCCAI; physician: SCCAI] were collected at baseline and follow-up visits every 6 months. Correlations between these measures were assessed using Spearman's rank correlation coefficient. Results Overall, 1804 evaluable patients had ≥1 follow-up visit. Over 24 months, mean [SD] disease severity measured by P-SCCAI/SCCAI reduced significantly from 4.2 [3.6]/3.0 [3.0] to 2.4 [2.7]/1.3 [2.1] [ p <0.0001]. Patient-/physician-assessed suffering, quantified by PRISM, reduced significantly over 24 months [ p <0.0001]. P-SCCAI/SCCAI and patient-/physician-assessed PRISM showed strong pairwise correlations [rho ≥0.60, p <0.0001], although physicians consistently underestimated these disease severity and suffering measures compared with patients. Patient-assessed PRISM moderately correlated with other outcome measures, including SIBDQ, PHQ-9, P-SCCAI, and SCCAI (rho = ≤-0.38 [negative correlations] or ≥0.50 [positive correlations], p <0.0001). Conclusions Over 2 years, disease burden and suffering, quantified by PRISM, improved in patients with relatively early UC. Physicians underestimated burden and suffering compared with patients. PRISM correlated with other measures of illness perception in patients with UC, supporting its use as an endpoint reflecting patient suffering. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

12. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease

Author

Olga Prymak, Grażyna Rydzewska, Per M. Hellström, Silvio Danese, Geert R. D'Haens, David Laharie, Gottfried Novacek, Mathurin Fumery, Mélanie Serrero, Erik Hertervig, Xavier Hébuterne, Peter Bossuyt, Remo Panaccione, Mircea Diculescu, Vincent W. Joustra, Benjamin Pariente, Jean-Frederic Colombel, J Butler, Walter Reinisch, Clara Yzet, Laurent Peyrin-Biroulet, Marc Ferrante, Francesca Petralia, Thomas Vanasek, Fernando Gomollón, Oleksandr Golovchenko, J Petersson, Jonas Halfvarson, Filip Baert, John P. Wright, Simon Travis, Gerhard Rogler, Adrian Goldis, Ryan C. Ungaro, Alessandro Armuzzi, Carol Stanciu, Irina Gubonina, Satoshi Motoya, Stefan Schreiber, Ungaro, Ryan C, Yzet, Clara, Bossuyt, Peter, Baert, Filip J, Vanasek, Thoma, D'Haens, Geert R, Joustra, Vincent Wilhelmu, Panaccione, Remo, Novacek, Gottfried, Reinisch, Walter, Armuzzi, Alessandro, Golovchenko, Oleksandr, Prymak, Olga, Goldis, Adrian, Travis, Simon P, Hébuterne, Xavier, Ferrante, Marc, Rogler, Gerhard, Fumery, Mathurin, Danese, Silvio, Rydzewska, Grazyna, Pariente, Benjamin, Hertervig, Erik, Stanciu, Carol, Serrero, Melanie, Diculescu, Mircea, Peyrin-Biroulet, Laurent, Laharie, David, Wright, John P, Gomollón, Fernando, Gubonina, Irina, Schreiber, Stefan, Motoya, Satoshi, Hellström, Per M, Halfvarson, Jona, Butler, James W, Petersson, Joel, Petralia, Francesca, Colombel, Jean-Frederic, Gastroenterology and Hepatology, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Time Factors, IBD, Anti-Inflammatory Agents, Lower risk, Severity of Illness Index, Article, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Crohn Disease, Interquartile range, Internal medicine, Azathioprine, Medicine, Humans, Retrospective Studies, Crohn's disease, Hepatology, business.industry, Proportional hazards model, Tumor Necrosis Factor-alpha, Hazard ratio, Remission Induction, Gastroenterology, Adalimumab, medicine.disease, Inflammatory Bowel Diseases, Crohn's Disease Activity Index, Confidence interval, Hospitalization, 030104 developmental biology, Treatment Outcome, Disease Progression, Prednisone, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Female, Calprotectin, CDEIS, business, Follow-Up Studies
Abstract

BACKGROUND & AIMS: We investigated the effects of inducing deep remission in patients with early Crohn's disease (CD). METHODS: We collected follow-up data from 122 patients (mean age, 31.2 ± 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1-0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05-6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period. RESULTS: Major adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P = .01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.07-0.31) was significantly associated with a lower risk of major adverse outcome. CONCLUSIONS: In an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of disease progression over a median time of 3 years, regardless of tight control or conventional management strategy. ispartof: GASTROENTEROLOGY vol:159 issue:1 pages:139-147 ispartof: location:United States status: published

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results